Preemies' Blood Type Tied to Risk for Necrotizing Enterocolitis
By LabMedica International staff writers Posted on 21 Jul 2021 |

Image: Axiom Genome-Wide Population-Optimized Human Arrays are genotyping panels that offer the best genetic coverage of rare and common variants for genome-wide disease association studies (Photo courtesy of Thermo Fisher Scientific)
Necrotizing enterocolitis (NEC) and focal intestinal perforation (FIP) are two of the most common emergencies of the gastrointestinal tract in preterm infants with very low birth weight (VLBW). The etiology and pathogenesis of NEC and FIP remain poorly understood.
Although FIP and NEC have been recognized as distinct entities, the clinical features and timing of presentation are frequently overlapping, making both diseases clinically indistinguishable in many cases. NEC typically occurs in infants born between 22 and 28 weeks of gestation within the second or third week of life. The gestational age of children developing FIP ranges between 22 and 27 weeks with intestinal perforation occurring within the first or second week of life.
Pediatricians at the University of Leipzig (Leipzig, Germany) and their colleagues enrolled in a prospective cohort study infants with a birth weight below 1,500 grams and gestational age below 37 weeks from 43 participating tertiary German neonatal intensive care units. The study included 10,257 infants with very low birth weight, 441 of whom required surgery for NEC/FIP. Data were collected from every infant on important maternal, fetal, and neonatal parameters, including maternal ethnic origin, sex, singleton versus multiple births, fetal malformation, pharmacological or surgical treated patent ductus arteriosus (PDA), sepsis, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL).
Patients’ data and samples were coded before genotyping and analysis. DNA was extracted using standard protocols for commercial DNA purification kits (Gentra Puregene Tissue Kit, Qiagen, Hilden, Germany). Chip genotyping was done by using ‘Axiom CEU’ (Affymetrix, Santa Clara, CA, USA) or by using ‘Global Screening Array (GSA)’ (Illumina, San Diego, CA, USA). The ABO gene was determined according to two SNPs (rs8176746 and rs8176719).
The team reported that most infants had type A blood (46.5%), followed by type O (34.5%), type B (13%), and type AB (6%). In regards to birth weight, mode of delivery, gestational age, gender, and corticosteroid exposure, no differences were reported according to blood type. Most infants had an average gestational age of 28.5 weeks, and the average birth weight was 1,051 grams for the AB blood group and 1,037 grams for the non-AB group. NEC/FIP requiring surgery was observed in 6.2% of infants with AB blood versus 4.2% of those with non-AB blood and 4.4% of those with type O blood. Mortality from NEC/FIP was 7.7% for the AB blood type group and 6.8% for the non-AB blood groups.
The authors concluded that they had demonstrated that among VLBW infants, blood group AB is associated with an increased risk of NEC/FIP. Therefore, blood group AB may be considered as an additional risk factor for NEC/FIP. The underlying mechanism of the blood group AB in NEC/FIP development, including potential interactions between intestinal bacteria and histo-blood group antigens (HBGAs) needs to be further elucidated. The study was published on July 2, 2021 in the journal Nature Scientific Reports.
Related Links:
University of Leipzig
Qiagen
Affymetrix
Illumina
Although FIP and NEC have been recognized as distinct entities, the clinical features and timing of presentation are frequently overlapping, making both diseases clinically indistinguishable in many cases. NEC typically occurs in infants born between 22 and 28 weeks of gestation within the second or third week of life. The gestational age of children developing FIP ranges between 22 and 27 weeks with intestinal perforation occurring within the first or second week of life.
Pediatricians at the University of Leipzig (Leipzig, Germany) and their colleagues enrolled in a prospective cohort study infants with a birth weight below 1,500 grams and gestational age below 37 weeks from 43 participating tertiary German neonatal intensive care units. The study included 10,257 infants with very low birth weight, 441 of whom required surgery for NEC/FIP. Data were collected from every infant on important maternal, fetal, and neonatal parameters, including maternal ethnic origin, sex, singleton versus multiple births, fetal malformation, pharmacological or surgical treated patent ductus arteriosus (PDA), sepsis, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL).
Patients’ data and samples were coded before genotyping and analysis. DNA was extracted using standard protocols for commercial DNA purification kits (Gentra Puregene Tissue Kit, Qiagen, Hilden, Germany). Chip genotyping was done by using ‘Axiom CEU’ (Affymetrix, Santa Clara, CA, USA) or by using ‘Global Screening Array (GSA)’ (Illumina, San Diego, CA, USA). The ABO gene was determined according to two SNPs (rs8176746 and rs8176719).
The team reported that most infants had type A blood (46.5%), followed by type O (34.5%), type B (13%), and type AB (6%). In regards to birth weight, mode of delivery, gestational age, gender, and corticosteroid exposure, no differences were reported according to blood type. Most infants had an average gestational age of 28.5 weeks, and the average birth weight was 1,051 grams for the AB blood group and 1,037 grams for the non-AB group. NEC/FIP requiring surgery was observed in 6.2% of infants with AB blood versus 4.2% of those with non-AB blood and 4.4% of those with type O blood. Mortality from NEC/FIP was 7.7% for the AB blood type group and 6.8% for the non-AB blood groups.
The authors concluded that they had demonstrated that among VLBW infants, blood group AB is associated with an increased risk of NEC/FIP. Therefore, blood group AB may be considered as an additional risk factor for NEC/FIP. The underlying mechanism of the blood group AB in NEC/FIP development, including potential interactions between intestinal bacteria and histo-blood group antigens (HBGAs) needs to be further elucidated. The study was published on July 2, 2021 in the journal Nature Scientific Reports.
Related Links:
University of Leipzig
Qiagen
Affymetrix
Illumina
Latest Pathology News
- AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
- AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
- AI-Based Model Predicts Kidney Cancer Therapy Response
- Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
- World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
- Breakthrough Diagnostic Approach to Significantly Improve TB Detection
- Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more